EL7.AI
StocksMediumUpdated•Originally published 13 March 2026•Updated 14 March 2026•
1 min read

Jefferies Sets $30 Target for Mineralys Therapeutics Following Q4 Earnings Call

Key Facts

1Analyst Dennis Ding from Jefferies set a price target of $30 for MLYS, suggesting a potential upside of 14.37%.
2The Q4 2025 earnings call revealed strategic developments and growth plans in the cardiovascular and renal disease sectors.
3The stock has shown high volatility over the past year, ranging from a low of $10.44 to a high of $47.65.

Jefferies analyst Dennis Ding has issued a positive outlook for Mineralys Therapeutics (MLYS), setting a price target of $30 per share. This target implies a potential upside of 14.37% from current levels, reflecting confidence in the company's clinical pipeline. The recommendation follows the company’s Q4 2025 earnings call, where management outlined strategic growth plans within the cardiovascular and renal disease sectors. Despite the optimistic forecast, the stock has experienced significant volatility over the past year, trading between a low of $10.44 and a high of $47.65. Investors are closely monitoring the company's R&D progress as it seeks to address unmet medical needs in its core therapeutic areas. The bullish sentiment from Jefferies underscores the long-term potential of MLYS's specialized drug development programs.